Van der Rijt Biotechnology

Van der Rijt Biotechnology is a private biotechnology company focused on the development of novel therapeutic agents for metabolic diseases, including type 2 diabetes and obesity. The company specializes in the design and optimization of incretin mimetics, specifically targeting the GLP-1 and GIP receptors to improve glycemic control and promote weight loss. Based in the Netherlands, the firm leverages expertise in peptide chemistry and molecular pharmacology to advance its early-stage pipeline. Van der Rijt Biotechnology aims to address the growing global burden of metabolic syndrome through innovative drug candidates with improved pharmacokinetic profiles.